Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries
Liver International · 2025
DOI: 10.1111/liv.70390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Jeffrey V Lazarus und 20 weiteren Autor:innen. Beteiligte Einrichtung: City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA. Hauptthemen laut MEDLINE: Mass Screening, Diabetes Mellitus, Type 2, Health Care Costs, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, Echosens, Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), are highly prevalent among people living with type 2 diabetes, with estimated rates of 65.4% and 31.6%, respectively, globally. This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030.
Methods
Strategy 1 consisted of a one‐time universal screening of all adults living with diabetes. Strategy 2 involved biennial retesting of individuals who initially tested negative. The Fibrosis‐4 (FIB‐4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration‐controlled transient elastography (VCTE) for confirmatory assessment. Implementation costs were estimated based on the country‐specific prevalence of diabetes and included positive price variations that were aligned to monetary policy targets.
Results
Over 5 years, the estimated costs of Strategy 1 ranged from R$0.7–1.3 billion for Brazil, €346–617 million for Germany, ¥80–172 billion for Japan, SAR 3.7–6.0 billion for the KSA, €591–949 million for Spain and $2.7–15.2 billion for the US. Strategy 2 resulted in higher costs, ranging from R$1.2–2.0 billion for Brazil, €528–940 million for Germany, ¥121–262 billion for Japan, SAR 5.7–9.2 billion for the KSA, €0.9–1.4 billion for Spain and $4.1–23 billion for the US.
Conclusions
This study provides valuable guidance for policymakers and healthcare managers to integrate liver fibrosis screening strategies for people living with diabetes into national health budgets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
- Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.
- Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, New York, USA.
- Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
- Internal Medicine Department, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Jeffrey V Lazarus, Leire Agirre-Garrido, J Emilio Miralles-Sanchez, Melina I Manolas, Frank Tacke, Cristiane A Villela-Nogueira, Hussain Abdulrahman Al-Omar, Saleh A Alqahtani, Lamya Mohammed Yahya Alzubaidi, Meena Bansal, Kenneth Cusi, Scott D Isaacs, Didac Mauricio, Teruki Miyake, Rodrigo O Moreira, Shoko Nakazawa, Silvana Pannain, Juan M Pericàs, Michael Roden, Hirokazu Takahashi, Nicolai Brachowicz
Förderung
- Boehringer Ingelheim
- Echosens
- Novo Nordisk
Zitieren
APA
Lazarus, J. V., Agirre-Garrido, L., Miralles-Sanchez, J. E., Manolas, M. I., Tacke, F., Villela-Nogueira, C. A., Al-Omar, H. A., Alqahtani, S. A., Alzubaidi, L. M. Y., Bansal, M., Cusi, K., Isaacs, S. D., Mauricio, D., Miyake, T., Moreira, R. O., Nakazawa, S., Pannain, S., Pericàs, J. M., Roden, M., …, & Brachowicz, N. (2025). Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries. Liver International. https://doi.org/10.1111/liv.70390
Vancouver
Lazarus JV, Agirre-Garrido L, Miralles-Sanchez JE, Manolas MI, Tacke F, Villela-Nogueira CA, et al. Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries. Liver International. 2025. doi:10.1111/liv.70390
BibTeX
@article{Lazarus2025,
author = {Lazarus, Jeffrey V and Agirre-Garrido, Leire and Miralles-Sanchez, J Emilio and Manolas, Melina I and Tacke, Frank and Villela-Nogueira, Cristiane A and Al-Omar, Hussain Abdulrahman and Alqahtani, Saleh A and Alzubaidi, Lamya Mohammed Yahya and Bansal, Meena and Cusi, Kenneth and Isaacs, Scott D and Mauricio, Didac and Miyake, Teruki and Moreira, Rodrigo O and Nakazawa, Shoko and Pannain, Silvana and Pericàs, Juan M and Roden, Michael and Takahashi, Hirokazu and Brachowicz, Nicolai},
title = {Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70390}
}
EUVIMED